Low transthyretin is associated with the poor prognosis of colorectal cancer

被引:0
|
作者
Zhang, Zhe [1 ,2 ,3 ]
Hu, Chenhao [1 ,2 ,3 ]
Shi, Feiyu [1 ,2 ,3 ]
Zhang, Lei [1 ,2 ,3 ]
Wang, Ya [2 ,3 ]
Zhang, Yujie [1 ,2 ,3 ]
Zhang, Xiaojiang [1 ,2 ,3 ]
She, Junjun [1 ,2 ,3 ]
机构
[1] Xi An Jiao Tong Univ, Affiliated Hosp 1, Dept Gen Surg, Xian, Shaanxi, Peoples R China
[2] Xi An Jiao Tong Univ, Medx Inst, Affiliated Hosp 1, Ctr Gut Microbiome Res, Xian, Shaanxi, Peoples R China
[3] Xi An Jiao Tong Univ, Affiliated Hosp 1, Dept High Talent, Xian, Shaanxi, Peoples R China
来源
FRONTIERS IN ONCOLOGY | 2025年 / 15卷
基金
中国国家自然科学基金;
关键词
transthyretin; prognosis; colorectal cancer; clinicopathologic feature; cancer-specific survival; nomogram; MARKER;
D O I
10.3389/fonc.2025.1397019
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objective To determine whether transthyretin (TTR) influences the prognosis of patients with colorectal cancers and establish a predictive model based on TTR. Methods Between January 2013 and February 2019, the clinical data of 1322 CRC patients aged from 18 years to 80 years who underwent surgical treatment were retrospectively analyzed. The preoperative TTR level, clinicopathological data, and follow-up data were recorded. The X-tile program was used to determine the optimal cut-off value. Cox proportional hazard regression analysis was conducted to evaluate the correlation between the TTR and the cumulative incidence of cancer-specific survival (CSS). Nomograms were then developed to predict CSS. Furthermore, an additional cohort of 377 CRC patients enrolled between January 2014 and December 2015 was included as an external validation. Results Based on the optimal cut-off value of 121.3 mg/L, we divided the patients into the TTR-lower group (<121.3 mg/L) and the TTR-higher group (>= 121.3 mg/L). Comparative analysis revealed that the TTR-higher group exhibited a younger demographic, a higher prevalence of low colorectal cancers, an elevated R0 resection rate, superior differentiation, earlier stage and lower levels of carcinoembryonic antigen (CEA) in contrast to the TTR-lower group. The Cox multivariable analysis underscored the significance of TTR and various clinicopathological factors, encompassing age, tumor location, R0 resection status, differentiation grade, disease stage, postoperative chemoradiotherapy, and preoperative CEA levels, as substantial prognostic indicators. The postoperative survival nomogram, when internally and externally assessed, demonstrated commendable performance across multiple metrics, including the area under the receiver operating characteristic curve (AUC), calibration plots, and decision curve analysis (DCA). Compared with other models, the proportional hazards model combined with TTR demonstrates superior performance in terms of C-index, AUC, calibration chart, and DCA within the prognostic column chart. Conclusions The preoperative TTR was identified as a prognostic factor for predicting the long-term prognosis of CRC patients who underwent surgical treatment, supporting its role as a prognostic biomarker in clinical practice.
引用
收藏
页数:15
相关论文
共 50 条
  • [31] Long noncoding RNA ARSR is associated with a poor prognosis in patients with colorectal cancer
    Li, Ting
    Jin, Xuezhu
    Dong, Jingrong
    Deng, Houbo
    JOURNAL OF GENE MEDICINE, 2020, 22 (10):
  • [32] Perineural invasion is associated with poor prognosis of colorectal cancer: a retrospective cohort study
    Cao, Yinghao
    Deng, Shenghe
    Yan, Lizhao
    Gu, Junnan
    Li, Jiang
    Wu, Ke
    Cai, Kailin
    INTERNATIONAL JOURNAL OF COLORECTAL DISEASE, 2020, 35 (06) : 1067 - 1075
  • [33] Hypermethylation of heparanase 2 promotes colorectal cancer proliferation and is associated with poor prognosis
    Zhang, Hui
    Xu, Chenxin
    Shi, Chen
    Zhang, Junying
    Qian, Ting
    Wang, Zhuo
    Ma, Rong
    Wu, Jianzhong
    Jiang, Feng
    Feng, Jifeng
    JOURNAL OF TRANSLATIONAL MEDICINE, 2021, 19 (01)
  • [34] Methylation of bone morphogenetic protein 2 is associated with poor prognosis in colorectal cancer
    Miura, Tomiyuki
    Ishiguro, Megumi
    Ishikawa, Toshiaki
    Okazaki, Satoshi
    Baba, Hironobu
    Kikuchi, Akifumi
    Yamauchi, Shinichi
    Matsuyama, Takatoshi
    Uetake, Hiroyuki
    Kinugasa, Yusuke
    ONCOLOGY LETTERS, 2020, 19 (01) : 229 - 238
  • [35] Hypermethylation of heparanase 2 promotes colorectal cancer proliferation and is associated with poor prognosis
    Hui Zhang
    Chenxin Xu
    Chen Shi
    Junying Zhang
    Ting Qian
    Zhuo Wang
    Rong Ma
    Jianzhong Wu
    Feng Jiang
    Jifeng Feng
    Journal of Translational Medicine, 19
  • [36] Overexpression of GLUT1 in colorectal cancer is independently associated with poor prognosis
    Shen, Yang-Mei
    Arbman, Gunnar
    Olsson, Birgit
    Sun, Xiao-Feng
    INTERNATIONAL JOURNAL OF BIOLOGICAL MARKERS, 2011, 26 (03): : 166 - 172
  • [37] POORLY DIFFERENTIATED CLUSTERS HIGH GRADE IS ASSOCIATED WITH POOR PROGNOSIS IN COLORECTAL CANCER
    Kitajima, Takahito
    Toiyama, Yuji
    Okugawa, Yoshinaga
    Omura, Yusuke
    Yamamoto, Akira
    Ide, Shozo
    Shigemori, Tsunehiko
    Fujikawa, Hiroyuki
    Yasuda, Hiromi
    Hiro, Junichiro
    Yoshiyama, Shigeyuki
    Kobayashi, Minako
    Ohi, Masaki
    Araki, Toshimitsu
    Kusunoki, Masato
    GASTROENTEROLOGY, 2018, 154 (06) : S1062 - S1062
  • [38] High hnRNP AB expression is associated with poor prognosis in patients with colorectal cancer
    Zhou, Jun-Min
    Jiang, Hang
    Yuan, Tao
    Zhou, Guang-Xun
    Li, Xiang-Bing
    Wen, Kun-Ming
    ONCOLOGY LETTERS, 2019, 18 (06) : 6459 - 6468
  • [39] Perineural invasion is associated with poor prognosis of colorectal cancer: a retrospective cohort study
    Yinghao Cao
    Shenghe Deng
    Lizhao Yan
    Junnan Gu
    Jiang Li
    Ke Wu
    Kailin Cai
    International Journal of Colorectal Disease, 2020, 35 : 1067 - 1075
  • [40] Overexpression of MAGT1 is associated with aggressiveness and poor prognosis of colorectal cancer
    Zheng, Kehong
    Yang, Qianqiong
    Xie, Lang
    Qiu, Zhenghua
    Huang, Yongsheng
    Lin, Yongwei
    Tu, Lingjing
    Cui, Chunhui
    ONCOLOGY LETTERS, 2019, 18 (04) : 3857 - 3862